Rapino C.,University of Teramo |
Caprioli A.,Sigma-Tau Pharmaceuticals |
Borsini F.,Sigma-Tau Pharmaceuticals |
Maccarrone M.,University of Teramo |
And 2 more authors.
Behavioural Brain Research | Year: 2011
The endocannabinoid system is critically involved in the modulation of affect, motivation, and emotion. Here, we investigated the hypothesis that changes in the content of endocannabinoid levels might underlie adaptation to positive social conditions during adolescence. To this aim, separate pairs of adolescent (postnatal days 32-35) male Wistar rats were allowed to interact in a neutral cage under two different testing conditions, i.e. familiar (FAM) and non-familiar (NFAM) social partners. We found that adolescent rats that encountered a NFAM partner spent significantly more time Sniffing and Following the companion than subjects exposed to a FAM partner, whereas no changes in levels of rough-and-tumble play were observed. Notably, the NFAM social encounter significantly increased striatal anandamide (AEA) levels compared to both non-social controls and animals that encountered a FAM partner. Changes in AEA levels appeared to be region-specific, since no changes were observed in the other brain regions analysed, neither were they observed in the activity of the AEA-hydrolase (FAAH) nor in the content of the other major endocannabinoid 2-arachidonylglycerol. In addition, animals that encountered a NFAM partner tended to explore less extensively the illuminated compartment of the light-dark box when compared to animals that had previously encountered a FAM companion. In conclusion, striatal AEA levels seem to participate in the emotional arousal resulting from a NFAM social encounter in adolescent rats, and to be particularly important for coping response to novel social contexts. © 2011 Elsevier B.V.
News Article | March 1, 2017
GAITHERSBURG, Md.--(BUSINESS WIRE)--Sigma-Tau Pharmaceuticals, Inc., a leader in the development and commercialization of medicines for patients with rare diseases, today announced that the company has changed its name to Leadiant Biosciences, Inc. reaffirming the company’s continued strong commitment to the patient communities it serves. The announcement coincides with Rare Disease Day 2017, a global campaign to raise awareness of rare diseases and improve access to available treatments and medical representation for people, and their caregivers, whose lives are impacted by these conditions. Now in its 10th year, Rare Disease Day is an annual celebration organized by the European Organization for Rare Diseases (EURORDIS) and the National Organization for Rare Disorders (NORD). This year’s theme, With Research, Possibilities Are Limitless, underscores the importance of collaborative research in the drug-development process and recognizes the contributions of patients and families in advocating for increased investment in rare disease research. “Rare Disease Day is the perfect time to unveil our new name and reaffirm our commitment to the study of rare diseases, which has been an integral part of our heritage dating back to 1984 when we became only the fourth company in the world to receive an Orphan Drug Designation in the U.S.,” said Michael Minarich, chief executive officer, Leadiant Biosciences, Inc. “In 2017, Leadiant Biosciences will realize several important and exciting milestones in our product pipeline, as well as continuing multiple ongoing clinical trials.” For more information about the vision, mission and work of Leadiant Biosciences, Inc. visit www.leadiant.com. For more information about Rare Disease Day 2017, visit www.rarediseaseday.org or www.rarediseaseday.us. Leadiant Biosciences, Inc. (formerly Sigma-Tau Pharmaceuticals, Inc.) is a U.S.-based, wholly owned subsidiary of Leadiant Biosciences S.p.A., a research-based pharmaceutical company dedicated to the development and commercialization of medicines for patients with rare diseases. Based in Gaithersburg, Maryland, Leadiant Biosciences, Inc. dedicates considerable scientific and financial resources to the research, development, and distribution of novel and effective therapies that address patient needs and improve quality of life. For more information, visit www.leadiant.com.
News Article | November 1, 2016
Receive press releases from iHealthcareAnalyst, Inc.: By Email Nanomedicine Market USD 170 Billion by 2020, Published by iHealthcareAnalyst, Inc. Maryland Heights, MO, November 01, 2016 --( Visit the Nanomedicine Market 2013-2020 report at https://www.ihealthcareanalyst.com/report/nanomedicine-market/ Nanomedicine is the medical application of nanotechnology that ranges from the medical applications of nanomaterials and biological devices, to nanoelectronic biosensors, and even possible future applications of molecular nanotechnology such as biological machines. Nanomedicines are used globally to improve the treatments and lives of patients suffering from a range of disorders including ovarian and breast cancer, kidney disease, fungal infections, elevated cholesterol, menopausal symptoms, multiple sclerosis, chronic pain, asthma and emphysema. The global nanomedicine market segmentation is based on applications (neurology, cardiology, oncology, anti-inflammatory, anti-infectives, etc.). The global nanomedicine market report provides market size (Revenue USD Million 2013 to 2020), market share, market trends and forecasts growth trends (CAGR%, 2016 to 2020). The global nanomedicine market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. 1. Application 1.1 Neurology 1.2 Cardiology 1.3 Oncology 1.4 Anti-inflammatory 1.5 Anti-infectives 1.6 Others 2. Geography (Region, Country) 2.1 North America (U.S., Canada) 2.2 Latin America (Brazil, Mexico, Rest of LA) 2.3 Europe (U.K., Germany, France, Italy, Spain, Rest of EU) 2.4 Asia Pacific (Japan, China, India, Rest of APAC) 2.5 Rest of the World 3. Company Profiles 3.1 Abbott Laboratories 3.2 CombiMatrix Corporation 3.3 Celgene Corporation 3.4 Mallinckrodt plc 3.5 GE Healthcare 3.6 Johnson & Johnson 3.7 Merck & Company Inc. 3.8 Nanosphere, Inc. 3.9 Pfizer Inc. 3.10 Sigma-Tau Pharmaceuticals Inc. 3.11 Teva Pharmaceutical Industries Ltd. 3.12 UCB SA About Us iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals. iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas. Contact Us iHealthcareAnalyst, Inc. 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043 United States Email: firstname.lastname@example.org Website: https://www.ihealthcareanalyst.com Maryland Heights, MO, November 01, 2016 --( PR.com )-- The global nanomedicine market is estimated to reach USD 170 Billion in 2020, growing at a CAGR of 8.9% from 2016 to 2020, according to a market research report Nanomedicine Market 2013-2020, published by iHealthcareAnalyst, Inc.Visit the Nanomedicine Market 2013-2020 report at https://www.ihealthcareanalyst.com/report/nanomedicine-market/Nanomedicine is the medical application of nanotechnology that ranges from the medical applications of nanomaterials and biological devices, to nanoelectronic biosensors, and even possible future applications of molecular nanotechnology such as biological machines. Nanomedicines are used globally to improve the treatments and lives of patients suffering from a range of disorders including ovarian and breast cancer, kidney disease, fungal infections, elevated cholesterol, menopausal symptoms, multiple sclerosis, chronic pain, asthma and emphysema.The global nanomedicine market segmentation is based on applications (neurology, cardiology, oncology, anti-inflammatory, anti-infectives, etc.).The global nanomedicine market report provides market size (Revenue USD Million 2013 to 2020), market share, market trends and forecasts growth trends (CAGR%, 2016 to 2020). The global nanomedicine market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.1. Application1.1 Neurology1.2 Cardiology1.3 Oncology1.4 Anti-inflammatory1.5 Anti-infectives1.6 Others2. Geography (Region, Country)2.1 North America (U.S., Canada)2.2 Latin America (Brazil, Mexico, Rest of LA)2.3 Europe (U.K., Germany, France, Italy, Spain, Rest of EU)2.4 Asia Pacific (Japan, China, India, Rest of APAC)2.5 Rest of the World3. Company Profiles3.1 Abbott Laboratories3.2 CombiMatrix Corporation3.3 Celgene Corporation3.4 Mallinckrodt plc3.5 GE Healthcare3.6 Johnson & Johnson3.7 Merck & Company Inc.3.8 Nanosphere, Inc.3.9 Pfizer Inc.3.10 Sigma-Tau Pharmaceuticals Inc.3.11 Teva Pharmaceutical Industries Ltd.3.12 UCB SAAbout UsiHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.Contact UsiHealthcareAnalyst, Inc.2109, Mckelvey Hill Drive,Maryland Heights, MO 63043United StatesEmail: email@example.comWebsite: https://www.ihealthcareanalyst.com Click here to view the list of recent Press Releases from iHealthcareAnalyst, Inc.
News Article | February 28, 2017
LONDON--(BUSINESS WIRE)--Technavio’s latest report on the global lifestyle drugs market provides an analysis of the most important trends expected to impact the market outlook from 2017-2021. Technavio defines an emerging trend as a factor that has the potential to significantly impact the market and contribute to its growth or decline. The research study by Technavio on the global lifestyle drugs market for 2017-2021 provides detailed industry analysis based on therapy area (depression, dermatology, sexual dysfunction, and obesity) and geography (the Americas, EMEA, and APAC). The Americas will be the leading regional segment, generating both the highest revenue and maximum incremental growth through 2021. The vendors in this market space are working towards introducing new products to target emerging lifestyle diseases, which will immensely benefit this segment. Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more. The top three emerging trends driving the global lifestyle drugs market according to Technavio healthcare and life sciences research analysts are: Sapna Jha, one of the lead analysts at Technavio for cardiovascular and metabolic disorders, talks about the consolidation of the lifestyle drugs market through mergers and acquisitions (M&A). She says, “Vendors in the market are pursuing inorganic growth strategies to expand their lifestyle drugs portfolio and to improve their global presence. Also, with an increasing number of patent expires in the marketplace, vendors are also looking to enhance their portfolio through the acquisition of generics.” For instance, Concordia Healthcare completed the acquisition of the worldwide rights to four generic products. Similarly, Orexigen Therapeutics entered an agreement with Takeda Pharmaceuticals to acquire the US rights to Contrave for the treatment of obesity. Such initiatives will help vendors to expand their business horizons, thereby driving the market growth. Growing focus on development of drugs for new indications Vendors are increasing their focus on finding drugs to address new indications for which there are no drugs. Pharmaceutical companies are looking to monetize the unmet demands for these new indications to increase their product portfolio, income, and presence in the market. Female sexual dysfunction drugs are currently being researched as there is a huge potential customer base for the disease. Vendors such as Pfizer, Sigma-Tau Pharmaceuticals, VIVUS, Palatin Technologies, and TherapeuticsMD are increasingly looking to gain approval for female dysfunction products. These new drugs will add significant revenue to the market. Changing lifestyles of the general populace are giving rise to diseases related to these changes. Obesity and anti-aging products are two of the most sought after drugs from this sector. Vendors are responding to this demand by developing and launching new drugs targeting these diseases. “Vendors such as Rhythm Pharmaceuticals, Merck, AstraZeneca, Novo Nordisk, and Avolynt are some of the vendors that are trying to tap this growing market segment. Therefore, emerging lifestyle diseases are likely to create substantial growth opportunities for vendors, thereby driving market growth,” says Sapna. Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like cardiovascular devices, in-vitro diagnostics, and medical imaging. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently. Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies. Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, resellers, and end-users. If you are interested in more information, please contact our media team at firstname.lastname@example.org.
Palermo V.,University of Rome La Sapienza |
Falcone C.,University of Rome La Sapienza |
Calvani M.,Sigma-Tau Pharmaceuticals |
Mazzoni C.,University of Rome La Sapienza
Aging Cell | Year: 2010
In this work we report that carnitines, in particular acetyl-L-carnitine (ALC), are able to prolong the chronological aging of yeast cells during the stationary phase. Lifespan extension is significantly reduced in yca1 mutants as well in rho 0 strains, suggesting that the protective effects pass through the Yca1 caspase and mitochondrial functions. ALC can also prevent apoptosis in pro-apoptotic mutants, pointing to the importance of mitochondrial functions in regulating yeast apoptosis and aging. We also demonstrate that ALC attenuates mitochondrial fission in aged yeast cells, indicating a correlation between its protective effect and this process. Our findings suggest that ALC, used as therapeutic for stroke, myocardial infarction and neurodegenerative diseases, besides the well-known anti-oxidant effects, might exert protective effects also acting on mitochondrial morphology.
Sigma-Tau Pharmaceuticals | Date: 2014-02-27
Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system including diabetes and metabolic diseases, the respiratory system, the musculoskeletal system, the genitourinary system, for the treatment of inflammatory disorders, for use in dermatology, in haematology, in oncology in transplantation, in ophthalmology, for use in the gastroenterological areas and the prevention and treatment of ocular disorders or diseases, anti-infectives, pharmaceutical preparations treating bacterial-based disease, antivirals, antibiotics, antifungals, vaccines, diagnostic preparations for medical use.
Sigma-Tau Pharmaceuticals | Date: 2014-03-31
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
Sigma-Tau Pharmaceuticals | Date: 2014-09-19
News Article | February 19, 2014
Researchers are always looking for the Achilles’ heel of cancer—some weakness in tumor cells that can be attacked by drugs while leaving normal cells unharmed. Austin, TX-based Aeglea BioTherapeutics is trying to exploit a vulnerability that might make it possible to starve certain cancers to death. In some tumors, the cells can no longer make one of the building blocks of proteins, an amino acid called arginine. That’s usually no problem—the tumor can import arginine from the bloodstream and continue growing. But Aeglea is developing a drug designed to dry up the blood’s supply of arginine long enough to kill the cancer cells. “The tumor’s getting a free lunch and it can’t survive without it,” says Aeglea CEO David Lowe. By contrast, normal cells may be able to make the amino acid themselves or ride out the shortage. Aeglea’s lead drug candidate is an engineered human enzyme that breaks up molecules of arginine, making the amino acid unavailable as a nutrient in the bloodstream. That enzyme, arginase (AERase), and two others acquired by Aeglea, were created in the lab of University of Texas at Austin professor George Georgiou. Georgiou and his collaborator Everett Stone are scientific founders of Aeglea, which was formed last year to develop the engineered enzymes as drugs. Aeglea recently submitted a grant proposal to the Cancer Prevention and Research Institute of Texas (CPRIT), a $3 billion state fund that resumed operations in December after a suspension while state authorities investigated its methods of awarding grants. The possibility of winning CPRIT money was part of the draw that had led Aeglea to locate in Texas, Lowe says. The chance of gaining non-dilutive capital also helped the company close a $12 million Series A fundraising round in December co-led by Lilly Ventures and Novartis Bioventures, he says. A maker of biologic drugs, KBI Biopharma, is providing manufacturing support as Aeglea’s strategic partner. The CPRIT money would also come in handy, Lowe says. But Aeglea will do fine even if it doesn’t win a grant, he says. “CPRIT is icing on the cake for us,” Lowe says. “The company isn’t going away without it.” Aeglea’s drug development program builds on scientific insights that go back decades. Researchers had noted that some tumors developed malfunctioning pathways for the creation of certain amino acids, making them dependent on outside supplies. One drug class that takes advantage of such a weakness began gaining approvals back in the mid-1990s. Those drugs attack a cancer cell type that needs to import the amino acid asparagine. Enzymes called asparaginases, which break down asparagine, are now used in combination therapy regimens to treat acute lymphoblastic leukemia by depriving the cancer cells of the molecule. Drugs currently sold in the United States include pegaspargase (Oncaspar) from Sigma-Tau Pharmaceuticals of Gaithersburg, MD, and Dublin, Ireland-based Jazz Pharmaceuticals’ asparaginase Erwinia chrysanthemi (Erwinaze.) Although such asparaginase drugs, derived from microbial enzymes, have been used for 20 years, patients must sometimes switch from one to the other if they develop hypersensitivity to one of the drugs. For example, one of the most common side effects of Oncaspar is allergic reactions. Aeglea is trying to starve tumors that are dependent on a different amino acid, arginine. In these tumors, the gene for an enzyme needed to produce arginine, argininosuccinate synthetase, has lost its activity. The inability to make arginine is seen in a wide range of cancer types, including melanoma and liver, kidney, and prostate cancer, according to a 2012 paper by Georgiou and Stone. The company hopes to avoid the kind of immune system reactions seen with the microbe-derived asparaginase by making its drug from human enzymes. Lowe says Aeglea is now learning from the findings of a potential competitor, San Diego, CA-based Polaris Pharmaceuticals, which is also developing an enzyme designed to deplete the blood supply of arginine. The lead drug candidate from Polaris, ADI-PEG 20, is in a late stage trial for the most common form of liver cancer, hepatocellular carcinoma. “That enzyme is really paving the way for us,” Lowe says. “But … Next Page »